Septerna (NASDAQ:SEPN) Stock Price Down 6.6% - What's Next?

Key Points

• Septerna, Inc. (NASDAQ:SEPN) shares fell by 6.6% to $12.91, marking a significant decline in mid-day trading with volume down by 80% compared to the average session.
• Analyst ratings remain mixed; while HC Wainwright has a "buy" rating with a price target of $26.00, other firms suggest more conservative targets between $18.00 and $25.00.
• The company's recent quarterly earnings report showed a loss of ($0.49) per share, falling short of analysts' expectations, with expected EPS of -7.11 for the current fiscal year.

Shares of Septerna, Inc. (NASDAQ:SEPN - Get Free Report) dropped 6.6% on Tuesday . The company traded as low as $12.25 and last traded at $12.91. Approximately 142,574 shares traded hands during mid-day trading, a decline of 80% from the average daily volume of 730,508 shares. The stock had previously closed at $13.83.

Analyst Upgrades and Downgrades

SEPN has been the subject of a number of research analyst reports. Wells Fargo & Company raised their price target on Septerna from $11.00 to $18.00 and gave the company an "equal weight" rating in a research report on Friday, May 16th. HC Wainwright initiated coverage on Septerna in a research report on Monday, June 23rd. They issued a "buy" rating and a $26.00 price target for the company. Finally, Cantor Fitzgerald raised their price target on Septerna from $20.00 to $25.00 and gave the company an "overweight" rating in a research report on Friday, May 16th. One equities research analyst has rated the stock with a hold rating and four have issued a buy rating to the company's stock. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $26.75.

Septerna Stock Performance

The business has a 50 day moving average of $11.16 and a 200 day moving average of $9.61.

Septerna (NASDAQ:SEPN - Get Free Report) last posted its quarterly earnings data on Thursday, May 15th. The company reported ($0.49) EPS for the quarter, missing analysts' consensus estimates of ($0.38) by ($0.11). The company had revenue of $0.22 million during the quarter. Research analysts expect that Septerna, Inc. will post -7.11 EPS for the current year.

Institutional Trading of Septerna

Large investors have recently made changes to their positions in the stock. Tower Research Capital LLC TRC acquired a new stake in Septerna in the 4th quarter worth about $25,000. Legal & General Group Plc acquired a new stake in Septerna in the 4th quarter worth about $42,000. Summit Investment Advisors Inc. acquired a new stake in Septerna in the 4th quarter worth about $45,000. BNP Paribas Financial Markets acquired a new stake in Septerna in the 4th quarter worth about $52,000. Finally, KLP Kapitalforvaltning AS acquired a new stake in Septerna in the 1st quarter worth about $49,000.

About Septerna

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases.